Lite Strategy, Inc. Cost of Revenue
Lite Strategy, Inc. (LITS) reported Cost of Revenue of $0 for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-08.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2022-09-08
- Lite Strategy, Inc. cost of goods and services sold for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. cost of goods and services sold for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. cost of goods and services sold for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. cost of goods and services sold for the quarter ending 2021-03-31 was $405.00K, a 52.91% decline year-over-year.
- Lite Strategy, Inc. cost of goods and services sold for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Lite Strategy, Inc. cost of goods and services sold for fiscal 2021 was $1.41M, a 47.29% decline from fiscal 2020.
- Lite Strategy, Inc. cost of goods and services sold for fiscal 2020 was $2.67M, a 37.34% decline from fiscal 2019.
- Lite Strategy, Inc. cost of goods and services sold for fiscal 2019 was $4.26M, a 26.01% increase from fiscal 2018.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2022-06-30 | $0.00 10-K · filed 2022-09-08 | |||
| 2021-12-31 | $0.00 10-Q/A · filed 2022-05-23 | $0.00 10-Q/A · filed 2022-05-23 | $0.00 derived: sum of 3 quarters · filed 2022-09-08 | $405.00K derived: sum of 4 quarters · filed 2022-09-08 |
| 2021-09-30 | $0.00 10-Q/A · filed 2022-05-23 | $0.00 derived: sum of 2 quarters · filed 2022-09-08 | $405.00K derived: sum of 3 quarters · filed 2022-09-08 | $899.00K derived: sum of 4 quarters · filed 2022-09-08 |
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $405.00K derived: sum of 2 quarters · filed 2022-09-08 | $899.00K derived: sum of 3 quarters · filed 2022-09-08 | $1.41M 10-K · filed 2022-09-08 |
| 2021-03-31 | $405.00K 10-Q · filed 2022-05-23 | $899.00K derived: sum of 2 quarters · filed 2022-05-23 | $1.41M 10-Q · filed 2022-05-23 | $1.89M derived: sum of 4 quarters · filed 2022-09-08 |
| 2020-12-31 | $494.00K 10-Q/A · filed 2022-05-23 | $1.00M 10-Q/A · filed 2022-05-23 | $1.49M derived: sum of 3 quarters · filed 2022-09-08 | $2.35M derived: sum of 4 quarters · filed 2022-09-08 |
| 2020-09-30 | $509.00K 10-Q/A · filed 2022-05-23 | $991.00K derived: sum of 2 quarters · filed 2022-09-08 | $1.85M derived: sum of 3 quarters · filed 2022-09-08 | $2.49M derived: sum of 4 quarters · filed 2022-09-08 |
| 2020-06-30 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $1.34M derived: sum of 2 quarters · filed 2022-09-08 | $1.98M derived: sum of 3 quarters · filed 2022-09-08 | $2.67M 10-K · filed 2022-09-08 |
| 2020-03-31 | $860.00K 10-Q · filed 2021-05-06 | $1.50M derived: sum of 2 quarters · filed 2021-05-06 | $2.19M 10-Q · filed 2021-05-06 | $3.29M derived: sum of 4 quarters · filed 2022-05-23 |
| 2019-12-31 | $641.00K 10-Q · filed 2021-02-04 | $1.33M 10-Q · filed 2021-02-04 | $2.43M derived: sum of 3 quarters · filed 2022-05-23 | $3.59M derived: sum of 4 quarters · filed 2022-05-23 |
| 2019-09-30 | $688.00K 10-Q · filed 2020-11-10 | $1.79M derived: sum of 2 quarters · filed 2022-05-23 | $2.95M derived: sum of 3 quarters · filed 2022-05-23 | $3.96M derived: sum of 4 quarters · filed 2022-05-23 |
| 2019-06-30 | $1.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-05-23 | $2.27M derived: sum of 2 quarters · filed 2022-05-23 | $3.27M derived: sum of 3 quarters · filed 2022-05-23 | $4.26M 10-K/A · filed 2022-05-23 |
| 2019-03-31 | $1.16M 10-Q · filed 2020-05-07 | $2.17M derived: sum of 2 quarters · filed 2020-05-07 | $3.16M 10-Q · filed 2020-05-07 | $4.27M derived: sum of 4 quarters · filed 2020-09-09 |
| 2018-12-31 | $1.01M 10-Q · filed 2020-02-06 | $2.00M 10-Q · filed 2020-02-06 | $3.10M derived: sum of 3 quarters · filed 2020-09-09 | $4.04M derived: sum of 4 quarters · filed 2020-09-09 |
| 2018-09-30 | $989.00K 10-Q · filed 2019-11-07 | $2.10M derived: sum of 2 quarters · filed 2020-09-09 | $3.03M derived: sum of 3 quarters · filed 2020-09-09 | $3.75M derived: sum of 4 quarters · filed 2020-09-09 |
| 2018-06-30 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09 | $2.04M derived: sum of 2 quarters · filed 2020-09-09 | $2.77M derived: sum of 3 quarters · filed 2020-09-09 | $3.38M 10-K · filed 2020-09-09 |
| 2018-03-31 | $930.00K 10-Q · filed 2019-05-09 | $1.66M derived: sum of 2 quarters · filed 2019-05-09 | $2.28M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $728.00K 10-Q · filed 2019-02-07 | $1.35M 10-Q · filed 2019-02-07 | ||
| 2017-09-30 | $618.00K 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $5.00M 10-K · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |